Scleral buckling versus primary vitrectomy in patients with rhegmatogenous retinal detachment at high risk for failure to reattach
Methods: In a retrospective, nonrandomized study, 678 patients were identified from billing data as having RRD between April 1, 2010 and August 1, 2012 at one large retina practice. Patients were considered at high risk for failure to reattach if they presented with RRD in 2+ quadrants, retinal tears larger than 1 clock hour, preoperative proliferative vitreoretinopathy (PVR), or vitreous hemorrhage.
Results: 75 patients were identified as being at high risk for failure to reattach and were followed for a mean of 5.3 months. Patients treated with SB (n=44) were significantly more likely to have anatomic success after a single surgery compared to those treated with PPV alone (n=31) (75.0% for SB vs. 51.6% for PPV alone; p=0.049). Development of PVR and best-corrected visual acuity at 3 months post-procedure and final follow-up were not significantly different between the two treatment groups.
Conclusion: For patients with RRD at high risk for failure to reattach, SB was associated with significantly higher anatomical success rates compared to PPV alone.
Learning Areas:Basic medical science applied in public health
Clinical medicine applied in public health
Other professions or practice related to public health
Provision of health care to the public
Compare surgical treatments for patients with rhegmatogenous retinal detachment at high risk for failure to reattach
Keyword(s): Vision Care, Treatment Outcomes
Qualified on the content I am responsible for because: I have worked as a post-baccalaureate student and research assistant on multiple studies evaluating the safety and efficacy of medical and surgical interventions for retinal disease. Among my scientific interests are outcome results from clinical studies applied to the public health sphere.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.